Global Transplant Diagnostics Market

The influenza diagnostic market consists of sales of diagnostic tests used to diagnose influenza including viral culture, serology, rapid antigen testing, reverse transcription-polymerase chain reaction (RT-PCR), immunofluorescence assays, and rapid molecular assays. Influenza, commonly known as flu, is a contagious illness caused by the influenza virus. Three varieties of this virus affect people: type A, type B, and type C. Common symptoms include fever, sore throat, cough, body ache, fatigue, and headache. The market consists of revenues generated by establishments conducting the diagnostics tests for influenza virus detection. The influenza diagnostics market covered in this report is segmented by traditional diagnostic tests into rapid influenza diagnostic tests (RIDT), viral culture, DFA, serological assays, others. The influenza diagnostic market is also segmented by molecular diagnostic tests into reverse transcription-polymerase chain reaction (RT-PCR), isothermal nucleic acid amplification tests (INAAT), loop-mediated isothermal based amplification assays, transcription-mediated isothermal based amplification assays, other isothermal nucleic acid amplification tests, other molecular diagnostic tests and by end-user into hospitals & clinical laboratories, diagnostic reference laboratories, academic/research institutes, other end-users. The global influenza diagnostic market is expected to grow from $1.31 billion in 2020 to $1.33 billion in 2021 at a compound annual growth rate (CAGR) of 1.5%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The influenza diagnostic market is expected to reach $1.74 billion in 2025 at a CAGR of 7%. The major factor driving the market is increasing funding for research on influenza diagnostics. Addressing the public health impact of influenza disease requires a proper understanding of the virus and its effect on individuals and populations. Therefore, it is important to accelerate the pace of scientific research progress that can have the greatest public health impact. Many public and private health organizations, researchers, health professionals, biopharmaceutical companies have maximized the spending for research funds or grants to reduce the risk of the emergence of pandemic influenza. For instance, in 2019, the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health, has initiated the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, a new network of research centers that will work together to develop influenza vaccines. NIAID will provide up to approximately $51 million in total first-year funding for the program, which is designed to support the CIVICs program centers over seven years. The variability in sensitivity and specificity among the influenza diagnostic tests is restraining the growth of the market. In most rapid flu tests, there are difficulties in identifying patients with influenza. The sensitivity of rapid flu tests ranges from 10-80% across various patient populations. Most diagnostic tests show an increase in the rate of false-negative results during low influenza virus activity, which often leads to an incorrect diagnosis. Thus, the variability in sensitivity and specificity is restraining the growth of the influenza diagnostic market. Rapid influenza diagnostic tests (RIDTs) are increasingly being implemented in influenza diagnostics. RIDTs are immunoassays which can identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and display the result in a qualitative way (positive vs. negative). It can yield results in a clinically relevant time frame of less than approximately 15 minutes and diagnose patients, who are present with influenza-like illness, mainly if it is performed within the first four days of the onset of symptoms. The rising popularity of RIDT is due to the benefits such as simple to use and rapid diagnosis. In June 2019, Meridian Bioscience Inc., an international producer and distributor of a range of diagnostic test kits, completed its acquisition of GenePoc Inc., a Canadian provider of molecular diagnostic instruments and assays. Meridian will now include GenePOC’s state-of-the-art revogene molecular diagnostics platform, which offers samples to result in testing for single tests, as well as flexible multiplexing capability. GenePOC is a subsidiary of Debiopharm Group. It specializes in the development and commercialization of rapid molecular assays usable on the unique revogene platform for near-patient infectious disease diagnostic. In 2018, Siemens Healthineers acquired Fast Track Diagnostics for an undisclosed amount. By introducing Fast Track Diagnostics products to its molecular diagnostics portfolio, Siemens Healthineers is investing in precision medicine and better patient experience through solutions that eliminate the need for repeat diagnostic testing, reducing time and improving patient outcomes. Fast Track Diagnostics specializes in the design, development and manufacture of infectious disease detection kits that use syndromic multiplex real-time PCR. Major players in the influenza diagnostic market are F. Hoffmann-La Roche Ltd, Quidel Corporation, Thermo Fisher, Abbott Laboratories, Hologic, Becton, Dickinson and Company, DiaSorin S.p.A., Luminex Corporation, Meridian Bioscience, Inc., and GenMark Diagnostics. The regions covered in the influenza diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the influenza diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global influenza diagnostic market is segmented - 1) By Traditional Diagnostic Tests: Rapid Influenza Diagnostic Tests (RIDT), Viral Culture, DFA, Serological Assays, Others 2) By Molecular Diagnostic Tests: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification Tests (INAAT), Loop Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Other Isothermal Nucleic Acid Amplification Tests, Other Molecular Diagnostic Tests 3) By End User: Hospitals & Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Other End Users

The microbiology diagnostics devices and equipment market consists of sales of microbiology diagnostics devices and equipment and related services. Microbiology diagnostics devices and equipment are used to diagnose infectious diseases by examining pathogens. These instruments include incubators, autoclave sterilizers, anaerobic culture systems, blood culture systems, gram strainers, microscopes, mass spectrometers, molecular diagnostic instruments, reagents pathogen specific kits and general reagents. The market covered in the microbiology diagnostics devices and equipment market report is segmented by type into laboratory instruments, microbiology analysers; by end user into hospitals, diagnostic centres, customer lab service providers, academic institutes, research institutes; by laboratory instruments into incubators, gram stainers, bacterial colony counters, petri dish fillers, automated culture systems; by micro-biology analyzers into microbiology diagnostics instruments, microscopes; by reagents into pathogen-specific kits, general reagents. The global microbiology diagnostic devices and equipment market is expected to grow from $3.65 billion in 2020 to $4.36 billion in 2021 at a compound annual growth rate (CAGR) of 19.5%. The high growth is mainly due to the outbreak of COVID-19 that increased demand for the market. The microbiology diagnostics devices and equipment market is expected to reach $5.79 billion in 2025 at a CAGR of 7.3%. Increasing funding of public and private investments in the medical devices is driving the growth of microbiology diagnostic devices market. Increasing Investments indicates rising confidence of various private and public players on microbiology diagnostic devices thereby indicating a progressive increase and stimulating growth. For instance, India introduced ¥544 billion (~$4.90 billion) of medical devices in 2019 & transported ¥178 billion (~$1.60 billion) of medical devices with a market size at retail & institutional sales level of above ¥1500 billion (~$13.52 billion). It has the potential for above ¥ 1000 billion (~$9.02 billion) investment in medical devices over the next 5 years. The increasing investments on digital health technologies, artificial intelligence and non-invasive monitoring capability, delivery of gene therapy and regenerative medicines technologies, customized 3D printing of medical devices are expected to drive the microbiology diagnostic devices market. Unfavourable regulatory scenarios is one of the major restraints in the microbiology diagnosis devices market. In the US, section 510(k) of the Food, Drug and Cosmetic Act states that every device manufacturer must register with FDA and notify their intent to market a medical device at least 90 days in advance. These pre-market notifications are considered to be lengthy, rigorous and time-consuming processes for the approval of medical devices. If in case the submission fails due to some uncertainty, the company has to reperform all the tests and resubmit the premarket approval application. For instance, a 'Verticle Autoclave', a microbiology diagnostic device, complies with the strict international directives and standards such as capacity of 80-120 litre autoclave chamber volume, low sensitivity loads, restrictions on temperature calibration and a certificate from ISO17025 accreditation lab for temperature, pressure gauges & timer. Next Generation Sequencing (NGS) technologies are increasing their prevalence in the microbiology diagnostic devices market due to its cost effectiveness, sensitivity to detect low-frequency variants and comprehensive genomic coverage. Next Generation Sequencing (NGS) or high throughput sequencing or Massively Parallel Sequencing (MPS) is a method of sequencing genomes with an ability to sequence hundreds to thousands of genes or gene regions and capability to detect novel resistance genes (ARG) in bacteria. BioMérieux partnered with Illumina to develop bioMérieux EpiSe, a NGS service which will facilitate epidemiological monitoring of bacterial infections and monitor outbreaks in hospitals. Some of the modern next generation sequencing technologies that help to sequence DNA and RNA include Illumina (Solexa) sequencing, Roche 454 sequencing, Ion torrent Proton / PGM sequencing, and SOLiD sequencing. In April 2017, the European parliament approved the 2012 proposal of European Commission for regulations on in-vitro diagnostic Medical Devices (IVD) and other medical devices. The two new regulations replace the three existing directives on medical devices in order to enhance patient safety. These changes by the EU legislation aids in the development of microbiology diagnostic devices, as they focus on providing transparency of information through EUDAMED (the new European database of medical devices), allowing manufacturers to monitor products, stronger clinical evidence, post-market surveillance, and enhance safety improvements. In February 2019, Biomerieux, biotechnology company specialized in in vitro diagnostics, acquired Invisible Sentinel, a US-based company, for $75 million. This acquisition enables bioMérieux’s to expand its customer segments, innovative alternatives to deliver accurate results by rare pathogen testing and challenging food matrices. Invisible Sentinel provides microbial detection tools and devices for food and beverage molecular testing in order to improve safety, quality and productivity. These provide bioMérieux’s molecular food testing solution, 'GENE-UP®', an opportunity to adapt Invisible Sentinel assays to process high volumes of samples. Major players in the microbiology diagnostics devices and equipment market are Becton Dickinnson and Company, Biomerieux, Danaher, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories Inc., Bruker Corporation, Neogen Corporation, Merck KGaA, Charles River Laboratories International Inc, Don Whitley Scientific Limited, Quidel Corporation, Rapid Micro Biosystems Inc, Sartorius Group, 3M Company, TSI Inc, Vivione Biosciences, LLC, Hologic Inc., F. Hoffmann-La Roche AG, and Sartorius Group. The regions covered in the microbiology diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the microbiology diagnostics devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global microbiology diagnostic devices and equipment market is segmented - 1) By Type: Laboratory Instruments, Microbiology Analysers 2) By End User: Hospitals, Diagnostic Centres, Customer Lab Service Providers, Academic Institutes, Research Institutes 3) By Laboratory Instruments: Incubators, Gram Stainers, Bacterial Colony Counters, Petri Dish Fillers, Automated Culture Systems 4) By Micro-Biology Analyzers: Microbiology Diagnostics Instruments, Microscopes 5) By Reagents: Pathogen-Specific Kits, General Reagents

The blood transfusion diagnostics market consists of sales of blood transfusion diagnostics devices and related services. The related services here includes only installation and maintenance services offered by equipment manufacturers. Blood transfusion diagnostics are the devices which used to conduct tests before transfusion of blood from donor recipient such as blood grouping disease screening. The blood transfusion diagnostics market covered in this report is segmented by type into instruments and kits, reagents, others. The blood transfusion diagnostics market is also segmented by end user into hospitals, diagnostic laboratories, blood banks, plasma fractionation companies; by technology into western blot, ELISA, nucleic acid amplification, fluorescence assay, rapid test; by application into blood grouping, disease screening. The global blood transfusion diagnostics market is expected to grow from $3.82 billion in 2020 to $4.18 billion in 2021 at a compound annual growth rate (CAGR) of 9.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The blood transfusion diagnostics market is expected to reach $5.28 billion in 2025 at a CAGR of 6%. Patients undergoing surgical procedures need blood transfusion to replace the lost blood during the procedure. Blood transfusion diagnostics are used during the procedures to screen the blood before transferring it to the patient, and will otherwise increases incidence of infectious disease. According to Organization for Economic Co-operation and Development (OCED) in the UK, there were 491,604 surgical procedures in 2016 compared to 354,870 in 2006, a 38% increase. This increase in number of procedures will thereby drive the need for blood transfusion diagnostics. Developing and underdeveloped countries lack adequate blood banks, proper medical equipment for blood transfusion, adequate conditions for the storage of blood and low supply for a high demand of blood. Hospitals are not equipped with proper amenities that help provide hygienic and safe transfusions. For example, according to a research conducted by IndiaSpend, around 1.18 million units of blood was wasted during storage in the form of discoloration, bacterial contamination and expiry due to outdating. The poor infrastructure hampers the growth of the blood transfusion diagnostic market. The growing demand for advanced diagnostic measures and growing prevalence of infectious diseases associated with pathogens such as bacteria & viruses increase the preference for nucleic acid amplification testing (NAAT/NAT) to increase blood safety, improve efficiency and reduce turnaround time of the results. NAT is a technique that helps detect a particular nucleic acid, virus, or bacteria which acts as a pathogen in blood, tissue, or urine. NAT is highly sensitive and specific for viral nucleic acids and amplifies the region of targeted viral DNA and detects them earlier than the other traditional methods and narrows the period of infectious diseases. For example, XCRP Diagnostic Inc. and Luminex Corporations entered into a licensing agreement of XCR Diagnostic's Xtreme Chain Reaction Nucleic Acid Amplification Technology. In this deal, Luminex got the exclusive rights to use the XCR Diagnostic's NAAT technology for their future molecular diagnostic portfolio. The blood transfusion diagnostics market is highly regulated by governing bodies such as USFDA (the USA Food and Drug Administration), and Medicines and Healthcare products Agency (MHRA). For instance, the manufacturers and service providers in the USA must comply with the Center for Biologics Evaluation and Research (CBER) Regulations that have been published in the first chapter title 21 of Code of Federal Regulations (CFR). Part 600 of CFR 21 primarily focuses on the established standards like retention samples conditions, temperature to be maintained during shipment, sterilization of equipment's and role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. Major players in the blood transfusion diagnostics market are BAG Health Care GmbH, Grifols, Bio-Rad Laboratories, Inc., Abbott Laboratories and Immucor Inc. The regions covered in the blood transfusion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the blood transfusion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global blood transfusion diagnostics market is segmented - 1) By Type: Instruments and Kits, Reagents, Others 2) By End User: Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies 3) By Technology: Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence Assay, Rapid Test 4) By Application: Blood Grouping, Disease Screening

Diagnostic And Monitoring Ophthalmic Devices And Equipment Market Definition

The diagnostic and monitoring ophthalmic devices and equipment market consists of sales of diagnostic and monitoring ophthalmic devices and equipment and related services by entities (organizations, sole traders and partnerships) that manufacture diagnostic and monitoring ophthalmic devices and equipment. The diagnostic and monitoring ophthalmic devices are used for the diagnosis and monitoring of diseases related to the retina and cornea by measuring affix lenses and refractive errors. These devices also help to identify the power of the intra ocular lens (IOLs) and analyze the visual field. These devices include ultrasound imaging systems, optical coherence tomography scanners, ophthalmoscopes, corneal topographers, specular microscopes, slit lamps, fundus cameras, anomaloscope, haploscope, ophthalmic lens gauge, stereopsis measuring Instrument, retinoscopes, stereoscope and others.

The molecular diagnostics devices (or) equipment market consists of sales of molecular diagnostics devices and related services. Molecular diagnostics devices are used to diagnose infectious diseases and perform screening by detecting specific sequences in DNA or RNA at molecular level. It helps doctors to prescribe more accurate therapeutic interventions in the early stages of a disease. This market is segmented into instruments, reagents and consumables. The global molecular diagnostics devices and equipment market is expected to decline from $18.07 billion in 2020 to $13.57 billion in 2021 at a compound annual growth rate (CAGR) of -24.9%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $19.01 billion in 2025 at a CAGR of 8.8%. The growth in molecular diagnostic devices and equipment market is attributed to factors such as rapid rise in various bacterial and viral epidemics. The increase in the spread of diseases increases the demand for early and improved diagnostic methods. In order to improve the technology to enable early diagnosis of such diseases, Government and different organization’s extend their financial support towards the major key players of the industry. For example, according to the reports from Centres for Disease Control and Prevention (CDC) US, as on March 2019, 72 Zika virus disease cases were reported in U.S state and 148 Zika virus disease cases reported in US Territories. Thus, the rise of such chronic diseases serves as a prime driver for the players in the industry to develop more accurate and sophisticated diagnostic devices and equipment’s. Following the increase in demand of early diagnosis of Zika virus, Co-Diagnostics, Inc. in February 2019 launched its first multi-disease molecular diagnostic test for dengue, chikungunya and Zika. The regulatory process involving approval of molecular diagnostic tests is often slow. The lack of clear definition coupled with constant changes in the regulations is a challenge for companies developing these kits. In the developing nations such as India and China lack of well-defined regulatory framework negatively impacts the market, irrespective of the presence of a large population. In the US market, because of the changes in the rules and regulations, the products already in the market may also be required to go through Food and Drug Administration (FDA)’s pre-marketing approval process. For example, CLIA (Clinical Laboratory Improvement Amendments Act) in the US certifies the validity of a laboratory based tests but it does not regulate the clinical validity of molecular diagnostic tests. This means that it does not control whether these results are clinically correct. This argument puts a restraint to the industry and opens an argument that FDA should play a greater role in overseeing laboratories. The major players in the molecular diagnostic industry are focusing on developing automated solutions for devices and equipment’s used for molecular diagnostic processes. Automation of the process will help to enhance productivity and consistency of the whole diagnostic process. Computerisation of the diagnostic process gives reliable and efficient test results that manual testing by various experts does not. The major players of the industry are using nanotechnology based Oral Fluid Nano Sensor Test (OFNASET). The test uses a microfluidic-based nano sensor for the detection of oral cancer biomarkers in saliva. In order to keep up with the trend of automation and accuracy, Roche, created cobas connection modules (CCM) to improve scalability and sample-flow efficiency by allowing samples to automatically move between different systems and instruments. Thus, creating a fully automated work flow. The molecular diagnostic devices in the US are approved by Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH). These diagnostics devices are generally approved with an accompanying assay, in order to evaluate their safety and effectiveness or substantial equivalence with reference to the assays they run and the assay's defined performance parameters. However, the same instruments do not require FDA approval or clearance when used for basic scientific research-purposes. The European regulatory landscape has become more stringent and technically challenging for medical device companies. The introduction of four different risk classes of diagnostic device, i.e. classes A-D. Class A refers to lowest risk tests and class D refers to highest risk test such as HIV testing, blood grouping, and prenatal testing. Most of the genetic testing is classed into class C. The products bearing a CE mark, European approved tests, are safe to use and are in full compliance. In March 2019, Abbott received a CE mark for its Alinity m molecular diagnostic testing machine. This would allow it to sell the product across Europe. Major players in the market are Roche Ltd, Hologic, QIAGEN, Abbott, Danaher Corporation. The countries covered in the global molecular diagnostics devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global molecular diagnostics devices and equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global molecular diagnostics devices and equipment market is segmented - 1) By Product: Instruments, Reagents, Consumables 2) By End User: Diagnostic Laboratories, Hospitals, Others (Nursing Home, Blood Banks, Point of Care) 3) By Technology: DNA (Deoxyribonucleic acid) Sequencing, Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, Transcription Mediated Amplification (TMA), In situ Hybridization, Microarrays, Mass spectrometry, Others (Southern Blotting, Northern Blotting, Electrophoresis) 4) By Application: Cancer, Pharmacogenomics, Genetic Testing, Infectious Disease, Prenatal, Neurological Disease, Cardiovascular Disease

The hemostasis diagnostic devices and equipment market consists of sales of hemostasis diagnostic devices. Hemostasis is a process of slowing and stopping the blood flow to initiate wound healing after a vascular injury. Hemostasis is the first step of healing a wound, it happens in three main stages, blood coagulation, platelet plug formation and lastly vasoconstriction. There are three types of devices which help speed up the hemostasis process, vascular closure devices (VCD), compression devices, and there are bandages coated with agents which will speed the clotting process. With the help of hemostasis diagnostic devices, we can predict the cause of bleeding during surgery by identifying any hemostatic defects which patients may have. The global hemostasis diagnostic devices and equipment market is expected to grow from $1.93 billion in 2020 to $2.99 billion in 2021 at a compound annual growth rate (CAGR) of 54.9%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.27 billion in 2025 at a CAGR of 9.3%. The increased likelihood of older people being diagnosed with a disease is driving the number of surgeries such as cardio vascular diseases (CVD), using hemostasis devices. Due to the higher incidence of diseases with advancing age, there is an increase in the number of surgeries in elderly patients nowadays. These hemostasis devices are very efficient in speeding up the natural process of clotting in the blood and can monitor anticoagulation and transfusion therapy guidance in any surgery. According to the American Heart Association report, Americans older than 80 have a high risk of devolving a cardiovascular disease (CVD), around 83% of men and 87.1% of female will be suffering with any form of CVD, therefore, to improve the comfort of the patient and the success rate of surgeries as a result hemostasis device has been implemented widely. The use of hemostasis devices in hospitals or clinics requires a very lengthy approval procedure which is restraining the market. Before hemostasis devices can enter the market for commercial use they have to clear the regulations set by the Code of Federal Regulations (title 21). The process of approval consists firstly identification of the device, secondly classification of the device and finally the date of pre-market approval (PMA) or the notice of completion of prescription drug plan (PDP) is required. It is a very long and time-consuming approval process which discourages new entrants from entering this market. For example, Cardiva medical Inc. had to wait for a processing period of four months before they received approval to change the existing equipment with a newer and modern one. Emergence of new and improved technology in the hemostasis diagnostic device and equipment market. To improve the quality and success rate of operations, new and improved technology such as the collagen vascular hemostasis devices have been implemented. Collagen is the main structural protein found in skin and other connective tissues. It is widely used in purified form for cosmetic surgical treatments and has now emerged in the hemostasis diagnostic devices market. A patient can face immobility right after a femoral surgery leading to increased discomfort, as a result collagen-based closure device have been implemented. According to a study conducted by the American Journal of Neuroradiology which they surveyed 698 Angio-Seal closures, using the Angio seal reduced average time before mobilization by close to 15 minutes with no major complications. Angio seal is a type of collagen hemostasis device which reduces the average time of hemostasis and betters the mobilization of the patient. In the year 2018, Baxter international Inc., a leading American healthcare company acquired Mallinckrodt for $153 Million. The acquisition was done for the purchase and addition of hemostasis devices in the product portfolio of Baxter Inc. Mallinckrodt is an Irish–tax registered manufacturer of specialty pharmaceuticals and imaging agents. This acquisition was done to enhance the product portfolio of Baxter Inc. with hemostats, particularly Recothrom and Preveleak. These devices are useful in vascular reconstructions to achieve hemostasis by sealing the leakage mechanically. When the Preveleak hemostat device was implemented the average surgery, time was reduced by 15%. Major players in the market are C.R. Bard, Baxter International Inc., Pfizer Inc., Johnson & Johnson, Abbott Laboratories. The countries covered in the global hemostasis diagnostic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global hemostasis diagnostic devices and equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global hemostasis diagnostic devices and equipment market is segmented - 1) By Product: Analyzers, Coagulation Instrument, Other Hemostasis Instruments, Reagents and Kits 2) By End User: Hospitals, Clinics, Independent Diagnostic, Laboratories, Others 3) By Device Technology: Automated, Semi-Automated, Manual

Diagnostic Equipment Market Characteristics

The diagnostic devices (or) equipment market consists of sales of diagnostic equipment and related services by entities (organizations, sole traders and partnerships) that produce diagnostic equipment used in diagnosis of various diseases. This industry includes establishments that produce diagnosis equipment such as X-ray systems, ultrasound systems, computed tomography (CT) scanners, magnetic resonance imaging systems and other diagnostics equipment.

The medical and diagnostic laboratory services market consists of sales of medical and diagnostic laboratory services and related goods by entities (organizations, sole traders and partnerships) that provide diagnostics tests for various diseases. This industry includes CT scan centers, X-ray centers and other clinics that undertake disease diagnosis. The medical and diagnostic laboratory services market is segmented into medical laboratory services and diagnostic imaging centers. The global medical and diagnostic laboratory services market is expected to grow from $115.89 billion in 2020 to $125.53 billion in 2021 at a compound annual growth rate (CAGR) of 8.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $157.45 billion in 2025 at a CAGR of 6%. North America was the largest region in the global medical and diagnostic laboratory services market, accounting for 49% of the market in 2020. Asia Pacific was the second largest region, accounting for 23% of the global medical and diagnostic laboratory services market. Africa was the smallest region in the global medical and diagnostic laboratory services market. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. Tests to diagnose these diseases include HbA1c tests for monitoring diabetes, biopsies, tumor marker tests, bone scans, MRI and CT scans for diagnosis of various cancers, electrocardiograms, chest X-rays, cardiac CT scans and stress test for detection of cardiovascular diseases. The increase in the prevalence of lifestyle diseases will increase the demand for tests to diagnose these diseases and thus will drive the medical and diagnostic laboratory services market during the forecast period. The medical and diagnostic laboratory services market is expected to limit by the rising prevalence of self-care diagnostic equipment. These tools can be used by patients without assistance from medical personnel, to diagnose particular disabilities or disorders. Common self-care diagnostic devices include glucose monitoring devices, blood pressure monitoring devices, sleep apnea monitors and temperature monitors. The ease of use of self-care devices has increased demand for them during the last decade and is expected to increase it further during the forecast period. Some virtual applications are also aiding in diagnosis of certain health conditions. For instance, iPhone is working on an IOS accessory called Cue, which can be used as a home diagnostic kit. Self-care diagnostics is expected to have a negative impact on traditional medical and diagnostic laboratory services market during the forecast period by reducing the need for laboratory testing for some basic tests. Medical and diagnostic laboratories are using biomarkers to measure health parameters associated with individual wellness. The health and wellbeing of individuals can be measured by using biomarkers to assess factors behind sleep disorders and symptoms of stress. Biomarkers such as cortisol, testosterone, and secretory IgA can indicate changes in immune system relating to physical and mental conditions. This can be used by physicians to know the causative factors behind such conditions. This is a premium service primarily targeted at wealthy individuals and senior employees of corporations. The major players covered in the global medical and diagnostic laboratory services market are Quest Diagnostics Inc, Sonic Healthcare Limited, Eurofins, OPKO Health Inc, Medical And Diagnostic Laboratory Services. The countries covered in the global medical and diagnostic laboratory services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The regions covered in the global medical and diagnostic laboratory services market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global medical and diagnostic laboratory services market is segmented - 1) By Type: Diagnostic Imaging Centers, Medical Laboratory Services 2) By Application: Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, Others 3) By End User Gender: Male, Female 4) By Type of Expenditure: Public, Private Subsegments Covered: Computer Tomography (CT-Scan) Centers, Medical Radiological Laboratories, Dental or Medical X-Ray Laboratories, Ultrasound Imaging Centers, Magnetic Resonance Imaging (MRI) Centers